ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: TH-PO431

Urinary Calprotectin, Neutrophil Gelatinase Associated Lipocalin (NGAL), and KIM-1 in the Differentiation of Inflammatory vs. Noninflammatory CKD

Session Information

Category: CKD (Non-Dialysis)

  • 2102 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Authors

  • Seibert, Felix S., University Hospital Marien Hospital Herne, Herne, Germany
  • Westhoff, Timm H., University Hospital Marien Hospital Herne, Herne, Germany
Background

It has been demonstrated that urinary neutrophil gelatinase-associated lipocalin (NGAL) and calprotectin are helpful biomarkers in the differentiation of intrinsic and prerenal acute kidney injury. The present cross-sectional study investigates, whether urinary biomarkers are able to differentiate primarily inflammatory from non-inflammatory entities in chronic kidney disease (CKD).

Methods

Urinary calprotectin, NGAL and kidney injury molecule-1 (KIM-1) concentrations were assessed in a study population of 143 patients with stable CKD and 29 healthy controls. Stable renal function was defined as an eGFR fluctuation 5ml/min/1.73m2 in the past 12 months. Pyuria, metastatic carcinoma and renal transplantation were regarded as exclusion criteria. Diabetic nephropathy, hypertensive nephropathy, and polycystic kidney disease were categorized as “non-inflammatory renal diseases”, whereas glomerulonephritis and vasculitis were regarded as “inflammatory renal diseases”.

Results

Urinary calprotectin and NGAL concentrations significantly differed between CKD and healthy controls (p<0.05 each), whereas KIM-1 concentrations did not (p=0.84). Urinary calprotectin concentrations were numerically highest in glomerulonephritis/vasculitis (155.7 ng/ml), NGAL concentrations in diabetic and hypertensive nephropathy (18741 pg/ml), and KIM-1 concentrations in polycystic kidney disease (1556 pg/ml). However, the three biomarkers did neither show significant differences in-between the individual entities, nor the two categories of inflammatory vs. non-inflammatory renal diseases (calprotectin 155.7 vs. 96.99 ng/ml; NGAL 14896 vs. 11977 pg/ml; KIM-1 1388 vs. 1009 ng/ml; p>0.05 each).

Conclusion

The urinary biomarkers calprotectin, NGAL and KIM-1 have no diagnostic value in the differentiation of inflammatory vs. non-inflammatory etiologies of CKD.